EOE
MCID: ESP035
MIFTS: 40

Esophagitis, Eosinophilic, 1 (EOE) malady

Categories: Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Esophagitis, Eosinophilic, 1

Aliases & Descriptions for Esophagitis, Eosinophilic, 1:

Name: Esophagitis, Eosinophilic, 1 54 13
Eosinophilic Esophagitis 12 56 42 14 69
Eoe 56

Characteristics:

Orphanet epidemiological data:

56
eosinophilic esophagitis
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-5/10000 (Canada),1-5/10000 (Japan),1-5/10000 (Spain),1-5/10000 (Europe),1-5/10000 (United States),1-9/100000 (Switzerland),1-5/10000 (Switzerland); Age of onset: All ages; Age of death: normal life expectancy;

Classifications:



External Ids:

OMIM 54 610247
Disease Ontology 12 DOID:13922
ICD10 33 K20.0
ICD9CM 35 530.13
MeSH 42 D057765
NCIt 47 C27105
SNOMED-CT 64 235599003
Orphanet 56 ORPHA73247
ICD10 via Orphanet 34 K20
MESH via Orphanet 43 D057765
UMLS via Orphanet 70 C0341106
UMLS 69 C0341106

Summaries for Esophagitis, Eosinophilic, 1

OMIM : 54 Eosinophilic esophagitis (EOE) has an incidence of approximately 1 per 10,000 people. Symptoms include difficulty... (610247) more...

MalaCards based summary : Esophagitis, Eosinophilic, 1, also known as eosinophilic esophagitis, is related to eosinophilic enteropathy and esophagitis, and has symptoms including vomiting, failure to thrive and dysphagia. An important gene associated with Esophagitis, Eosinophilic, 1 is EOE1 (Esophagitis, Eosinophilic), and among its related pathways/superpathways are Akt Signaling and IL-17 Family Signaling Pathways. The drugs Budesonide and Lansoprazole have been mentioned in the context of this disorder. Affiliated tissues include esophagus, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 An esophagitis characterized by inflammation involving eosinophils located in esophagus.

Related Diseases for Esophagitis, Eosinophilic, 1

Diseases in the Esophagitis, Eosinophilic, 1 family:

Esophagitis, Eosinophilic, 2

Diseases related to Esophagitis, Eosinophilic, 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 121)
id Related Disease Score Top Affiliating Genes
1 eosinophilic enteropathy 11.1
2 esophagitis 10.9
3 autosomal dominant intellectual disability 30 10.9
4 extraskeletal ewing sarcoma 10.8
5 dahlberg borer newcomer syndrome 10.2 IL13 IL5
6 aortic atherosclerosis 10.2 IL13 IL5
7 renal hypertension 10.2 IL13 IL5
8 hypercementosis 10.2 IL13 IL5
9 spastic paraplegia 3a, autosomal dominant 10.2 IL13 IL5
10 peptidic growth factors deficiency 10.2 CCL11 IL5
11 natural killer cell leukemia 10.2 CCL11 IL5
12 exudative vitreoretinopathy 2, x-linked 10.2 IL13 IL5
13 paracoccidioidomycosis 10.2 ATP4A IER3IP1
14 indian plum allergy 10.2 IL13 IL5
15 gastroesophageal reflux 10.2
16 latent syphilis 10.2 CCL11 IL5
17 luminal breast carcinoma 10.2 IL13 IL5
18 necrotizing gastritis 10.1 CCL11 IL5
19 lactose intolerance 10.1 IL13 IL5
20 askin's tumor 10.1 IL13 IL5
21 lacrimal apparatus disease 10.1 ATP4A EPC2
22 smooth muscle tumor 10.1 IL13 IL5
23 cutaneous fibrous histiocytoma 10.1 CCL11 IL5
24 astrocytoma 10.1 CCL26 IL5
25 celiac disease 10.1
26 prostate small cell carcinoma 10.1 IL13 IL5
27 food allergy 10.1
28 cerebral primitive neuroectodermal tumor 10.1 CCL11 IL5 TSLP
29 apricot allergy 10.1 CCL11 IL5 TSLP
30 thelaziasis 10.1 CCL11 IL13 IL5
31 metal allergy 10.1 IL13 IL5
32 lymphoblastic leukemia 10.1 CCL11 IL13 IL5
33 spastic diplegia 10.1 CCL11 IL13 IL5
34 dysphagia 10.1
35 visceral steatosis 10.1 CCL11 IL13 IL5
36 intravascular angioleiomyoma 10.1 CCL11 IL13 IL5
37 ethmoid sinusitis 10.1 CCL11 IL13 IL5
38 childhood malignant mesenchymoma 10.1 CCL11 IL13 IL5
39 inflamed seborrheic keratosis 10.1 CCL11 IL13 IL5
40 hydrophthalmos 10.1 CCL11 IL13 IL5
41 thyroid hyalinizing trabecular adenoma 10.0 CCL11 IL13 IL5
42 acute dacryoadenitis 10.0 CCL11 IL13 IL5
43 pulmonary tuberculosis 10.0 CCL11 IL13 IL5
44 birth defects 10.0 CCL11 IL13 IL5
45 bare lymphocyte syndrome, type i 10.0 CCL11 IL13 IL5
46 malignant peritoneal solitary fibrous tumor 10.0 CCL11 IL13 IL5
47 glucocorticoid resistance 10.0 CCL11 IL13 IL5
48 rectum squamous cell carcinoma 10.0 CCL11 IL13 IL5
49 duodenal somatostatinoma 10.0 IL13 IL5
50 hypersensitivity vasculitis 10.0 IL5 STAT6

Graphical network of the top 20 diseases related to Esophagitis, Eosinophilic, 1:



Diseases related to Esophagitis, Eosinophilic, 1

Symptoms & Phenotypes for Esophagitis, Eosinophilic, 1

Symptoms by clinical synopsis from OMIM:

610247

Clinical features from OMIM:

610247

Human phenotypes related to Esophagitis, Eosinophilic, 1:

32
id Description HPO Frequency HPO Source Accession
1 vomiting 32 HP:0002013
2 failure to thrive 32 HP:0001508
3 dysphagia 32 HP:0002015
4 esophagitis 32 HP:0100633

UMLS symptoms related to Esophagitis, Eosinophilic, 1:


vomiting, epigastric pain

MGI Mouse Phenotypes related to Esophagitis, Eosinophilic, 1:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.7 IL13 IL5 POSTN STAT6 TSLP ATP4A
2 immune system MP:0005387 9.5 ATP4A CCL11 IL13 IL5 POSTN STAT6
3 respiratory system MP:0005388 9.02 CCL11 IL13 IL5 STAT6 TSLP

Drugs & Therapeutics for Esophagitis, Eosinophilic, 1

Drugs for Esophagitis, Eosinophilic, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 107)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Budesonide Approved Phase 4,Phase 3,Phase 2 51333-22-3 63006 5281004
2
Lansoprazole Approved, Investigational Phase 4,Phase 2,Phase 1 103577-45-3 3883
3
Menthol Approved Phase 4 2216-51-5 16666
4 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Phase 1
5 Cromolyn Sodium Phase 4
6 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1
7 Anti-Allergic Agents Phase 4,Phase 3,Phase 2,Phase 1
8 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
9 Autonomic Agents Phase 4,Phase 3,Phase 2
10 Bronchodilator Agents Phase 4,Phase 3,Phase 2
11 Dermatologic Agents Phase 4,Phase 3,Phase 2
12
Fluticasone Phase 4,Phase 3,Phase 2 90566-53-3, 80474-14-2 62924 22833648
13 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
14 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
15 Hormones Phase 4,Phase 3,Phase 2,Phase 1
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
17 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
18 Antacids Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
19 Anti-Ulcer Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
20
Dexlansoprazole Phase 4,Phase 2,Phase 1 138530-94-6, 103577-45-3 9578005
21 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
22
Proton pump inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
23 Olive Nutraceutical Phase 4
24 Soy Bean Nutraceutical Phase 4,Phase 2,Phase 3,Early Phase 1
25
Montelukast Approved Phase 3,Phase 1 158966-92-8 5281040
26
Esomeprazole Approved, Investigational Phase 2, Phase 3 161796-78-7, 119141-88-7 4594 9579578
27 Leukotriene Antagonists Phase 3,Phase 1
28
Omalizumab Approved, Investigational Phase 2,Phase 1 242138-07-4
29
Infliximab Approved Phase 2 170277-31-3
30
Losartan Approved Phase 2 114798-26-4 3961
31
Bethanechol Approved Phase 2 674-38-4 2370
32 Indoleacetic Acids Phase 2
33 Antirheumatic Agents Phase 2
34 Antibodies Phase 2,Phase 1
35 Antibodies, Monoclonal Phase 2,Phase 1
36 Immunoglobulins Phase 2,Phase 1
37 interferons Phase 1, Phase 2
38 Neurotransmitter Agents Phase 2
39 Pharmaceutical Solutions Phase 2
40
Angiotensin II Phase 2 68521-88-0, 11128-99-7 65143 172198
41 Angiotensin II Type 1 Receptor Blockers Phase 2
42 Angiotensin Receptor Antagonists Phase 2
43 Angiotensinogen Phase 2
44 Anti-Arrhythmia Agents Phase 2
45 Antihypertensive Agents Phase 2
46 Vasoconstrictor Agents Phase 2
47 mometasone furoate Phase 2 83919-23-7
48 Cholinergic Agents Phase 2
49
Lactulose Approved Phase 1 4618-18-2 11333
50
Mannitol Approved, Investigational Phase 1 69-65-8 453 6251

Interventional clinical trials:

(show top 50) (show all 112)
id Name Status NCT ID Phase
1 Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis Unknown status NCT02371941 Phase 4
2 Dietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis Unknown status NCT01846962 Phase 4
3 The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors Terminated NCT01404832 Phase 4
4 Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis Completed NCT00635089 Phase 3
5 Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years Completed NCT00538434 Phase 2, Phase 3
6 Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis Completed NCT02434029 Phase 3
7 A Study Comparing Swallowed Flovent and Placebo in Patients With Eosinophilic Disorders Completed NCT00266578 Phase 3
8 The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis Completed NCT00728481 Phase 2, Phase 3
9 Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis Recruiting NCT02493335 Phase 3
10 A Placebo- Controlled Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved Recruiting NCT02605837 Phase 3
11 An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE) Recruiting NCT02736409 Phase 3
12 Eosinophilic Esophagitis (EoE) Intervention Trial-Randomized 1 Food Elimination vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids Recruiting NCT02610816 Phase 2, Phase 3
13 SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study Recruiting NCT02778867 Phase 2, Phase 3
14 Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone Active, not recruiting NCT01702701 Phase 3
15 Safety and Efficacy of Three Doses of Oral Fluticasone Propionate in Adults With Eosinophilic Esophagitis Not yet recruiting NCT02873468 Phase 2, Phase 3
16 A Study of Flovent in Patients With Eosinophilic Esophagitis Completed NCT00426283 Phase 2
17 Budesonide for Eosinophilic Esophagitis Completed NCT00271349 Phase 2
18 Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis Completed NCT00762073 Phase 2
19 Topical Steroid Treatment for Eosinophilic Esophagitis Completed NCT00275561 Phase 2
20 Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis Completed NCT00638456 Phase 2
21 Proof of Concept Study of OC000459 in Eosinophilic Esophagitis Completed NCT01056783 Phase 2
22 Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis Completed NCT02098473 Phase 2
23 Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic Esophagitis Completed NCT02280616 Phase 2
24 Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis Completed NCT01386112 Phase 1, Phase 2
25 Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis Completed NCT01022970 Phase 2
26 A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab Completed NCT00123630 Phase 2
27 Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis Completed NCT00123656 Phase 2
28 Off Label Use of Infliximab in Adult Patients With Severe Eosinophilic Esophagitis Completed NCT00523354 Phase 2
29 OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension Completed NCT01642212 Phase 2
30 Intravenous Mepolizumab In Children With Eosinophilic Esophagitis Completed NCT00358449 Phase 2
31 An Evaluation Of Mepolizumab In Therapy Of Eosinophilic Oesophagitis In Adult Patients Completed NCT00274703 Phase 2
32 Omalizumab to Treat Eosinophilic Gastroenteritis Completed NCT00084097 Phase 2
33 Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome Completed NCT00017862 Phase 2
34 Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome Completed NCT00266565 Phase 1, Phase 2
35 Eosinophilic Esophagitis Clinical Therapy Comparison Trial Recruiting NCT01821898 Phase 2
36 An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) Recruiting NCT03029091 Phase 2
37 Milk Patch for Eosinophilic Esophagitis Active, not recruiting NCT02579876 Phase 2
38 Study of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis (EoE) Active, not recruiting NCT02379052 Phase 2
39 Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD Active, not recruiting NCT01808196 Phase 2
40 Mometasone-furoate for Treatment of Eosinophilic Esophagitis - a Randomized Placebo Controlled Study. Enrolling by invitation NCT02113267 Phase 2
41 Bethanechol for Eosinophilic Esophagitis Terminated NCT02058537 Phase 2
42 Predictors of Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Withdrawn NCT01479231 Phase 1, Phase 2
43 Evaluation of the Safety and Effectiveness of Tailored Transoral Incisionless Fundoplication (TIF) Using EsophyX for the Treatment of GERD Withdrawn NCT01025739 Phase 2
44 Observational Field Study of Acute Esophageal Food Bolus Impaction by Mean Esophageal Manometry and 24h-pH-monitoring Unknown status NCT01447823 Phase 1
45 Intestinal Permeability in Response to Treatment in Eosinophilic Esophagitis Patients Completed NCT01641913 Phase 1
46 Identifying Responders to Xolair (Omalizumab) Using Eosinophilic Esophagitis as a Disease Model Completed NCT01040598 Phase 1
47 Trial of Montelukast in Eosinophilic Esophagitis Completed NCT00511316 Phase 1
48 A Randomized Double Blind Placebo Controlled Study of the Effect of Swallowed Beclomethasone Dipropionate on Inflammatory Markers in Adult Patients With Eosinophilic Esophagitis Completed NCT01016223 Phase 1
49 Study to Identify Non-Invasive Markers of Gastrointestinal Allergy Completed NCT00272818 Phase 1
50 Using Spectrally Encoded Confocal Microscopy (SECM) to Image the Esophagus Recruiting NCT02202590 Phase 1

Search NIH Clinical Center for Esophagitis, Eosinophilic, 1

Cochrane evidence based reviews: eosinophilic esophagitis

Genetic Tests for Esophagitis, Eosinophilic, 1

Anatomical Context for Esophagitis, Eosinophilic, 1

The Foundational Model of Anatomy Ontology organs/tissues related to Esophagitis, Eosinophilic, 1:

18
Esophagus

Publications for Esophagitis, Eosinophilic, 1

Variations for Esophagitis, Eosinophilic, 1

Expression for Esophagitis, Eosinophilic, 1

Search GEO for disease gene expression data for Esophagitis, Eosinophilic, 1.

Pathways for Esophagitis, Eosinophilic, 1

GO Terms for Esophagitis, Eosinophilic, 1

Cellular components related to Esophagitis, Eosinophilic, 1 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.17 ATP4A CCL11 CCL26 IL13 IL5 POSTN

Biological processes related to Esophagitis, Eosinophilic, 1 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.46 CCL11 CCL26 IL13 IL5
2 positive regulation of actin filament polymerization GO:0030838 9.43 CCL11 CCL26
3 monocyte chemotaxis GO:0002548 9.4 CCL11 CCL26
4 positive regulation of B cell proliferation GO:0030890 9.37 IL13 IL5
5 positive regulation of receptor activity GO:2000273 9.32 CCL11 CCL26
6 lymphocyte chemotaxis GO:0048247 9.26 CCL11 CCL26
7 inflammatory response GO:0006954 9.26 CCL11 CCL26 IL13 IL5
8 cellular response to tumor necrosis factor GO:0071356 8.8 CCL11 CCL26 POSTN

Molecular functions related to Esophagitis, Eosinophilic, 1 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 chemokine activity GO:0008009 9.32 CCL11 CCL26
2 CCR chemokine receptor binding GO:0048020 9.26 CCL11 CCL26
3 receptor agonist activity GO:0048018 9.16 CCL11 CCL26
4 cytokine activity GO:0005125 9.02 CCL11 CCL26 IL13 IL5 TSLP
5 CCR3 chemokine receptor binding GO:0031728 8.96 CCL11 CCL26

Sources for Esophagitis, Eosinophilic, 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....